Opsens
10456, 176th Street
Suite 201
Edmonton
Alberta
T5S 1L3
Canada
Tel: 780-930-1777
Fax: 780-930-2077
Website: http://www.opsens.com/
60 articles about Opsens
-
OpSens to Host First Quarter Fiscal Year 2021 Financial Results Conference Call on Wednesday, January 13, 2021
1/6/2021
OpSens Inc. ("OpSens" or the "Company") (TSX: OPS) (OTCQX: OPSSF), a medical device cardiology-focused company delivering diagnostic and treatment solutions based on its proprietary optical technology, will report financial results for its first quarter of fis
-
OpSens Announces Fourth Quarter and Fiscal Year 2020 Financial Results
11/19/2020
OpSens Inc. ("OpSens" or the "Company") (TSX: OPS) (OTCQX: OPSSF) today reported its results for the fourth quarter and fiscal year 2020 ended August 31, 2020 . Financial Highlights Sales of product at $29.5 million in FY 2020 compared to prior FY 2019; Delivered Q4 2020 a $2.2 million improvement in
-
OpSens Recognized as One of the Fastest-Growing Company in North America on Deloitte's 2020 Technology Fast 500™
11/18/2020
OpSens Inc. has been recognized in Deloitte's 2020 Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences and energy tech companies in North America.
-
OpSens to Host Year-End Update Conference Call on Thursday, November 19, 2020
11/12/2020
OpSens Inc. ("OpSens" or the "Company") (TSX: OPS) (OTCQX: OPSSF), a medical device cardiology-focused company commercializing a second generation fiber optic pressure guidewire to diagnose and treat coronary disease, has scheduled a
-
OpSens Awarded Contract by Major U.S. Group Purchasing Organization
10/14/2020
OpSens Inc., a medical device cardiology-focused company commercializing a second-generation fiber optic pressure guidewire to diagnose and treat coronary disease, announced it has been awarded a 3-year contract by a major American Group Purchasing Organization.
-
OpSens to Present at Lytham Partners Virtual Investor Growth Conference
9/30/2020
OpSens Inc. ("OpSens" or the "Company") (TSX: OPS) (OTCQX: OPSSF), a medical device cardiology-focused company delivering diagnostic and treatment solutions based on its proprietary optical technology, will participate in a virtual presentation and fireside chat at the October 2020 Lytham Partners Virtual Inv
-
OpSens to Present at the LD 500 Virtual Conference
8/26/2020
OpSens Inc. today announced it will be presenting at the LD 500 investor conference on Tuesday, September 1st at 10:20 AM Eastern Time (7:20 AM Pacific Time).
-
OpSens Announces Result for Q3 2020
7/15/2020
Net earnings of $0.1 M for the third quarter ended May 31, 2020 compared with a net loss of $1.1 M for the corresponding period in 2019;
-
OpSens - 100,000 Cases Performed with the OptoWire
5/20/2020
OpSens Inc. reached an important milestone with more than 100,000 patients evaluated with the OptoWire™, a pressure guidewire for the diagnosis and treatment of coronary artery stenosis.
-
OpSens Announces Q2 2020 Results
4/9/2020
"In the midst of the Covid-19 crisis, OpSens is committed to its employees' overall safety while providing its customers continued access to its important technology," said Louis Laflamme, President and CEO of OpSens.
-
OpSens provides operational update - OpSens continues to supply essential cardiovascular solutions to patients around the world
3/24/2020
OpSens Inc., a cardiology-focused company delivering diagnostic and treatment solutions based on its proprietary optical technology, provided a business update in light of recent action taken by the province of Quebec regarding COVID-19.
-
Opsens - Election Results for the Board of Directors
1/22/2020
Opsens Inc. held its annual general and special shareholders' meeting in Quebec City, Canada..
-
Opsens - Announces Q1 2020 Results
1/13/2020
Consolidated product sales totaled $7.0 M in the first quarter of 2020 compared with $6.8 M in the corresponding period in 2019, an increase of 3%;
-
Opsens - Record FY2019 Consolidated Revenues of $32.8 M, Up 36%, Record FFR Revenues of $20M, Up 41%
11/14/2019
Record consolidated revenues at $32.8 M for FY2019 compared with $24.1 M for FY2018, a 36% increase
-
Opsens Announces Entry Into Structural Heart Market
11/5/2019
Opsens Inc. announces it is expanding its medical device business into the structural cardiology space and will accelerate development activities of products that reach beyond its current coronary and peripheral applications..
-
Opsens - Q3 2019 - Record Quarterly FFR Revenues of $5.2 M, Up 49%
7/11/2019
Opsens Inc. reported its results for the third quarter of 2019.
-
Opsens Solutions Further Expands Intellectual Property Portfolio with USPTO Grant
6/11/2019
Opsens Inc. announced that its wholly-owned subsidiary Opsens Solutions Inc., has been granted a patent for an innovative optical-based pressure sensor from the United States Patent and Trademark Office.
-
Opsens Signs Landmark Supplier Agreement - Expands Optical Sensing Technology Impact Within Cardiology Segment
4/30/2019
Opsens inc. is pleased to announce it has entered into a supply agreement as part of its long-term collaboration with Abiomed, Inc. for the Impella CP® heart pump.
-
Opsens - Q2 2019 Revenues Reach $7.9 M, a 46% Increase
4/11/2019
Opsens Inc. reported its results for the second quarter of 2019.
-
Opsens Appoints Alan Milinazzo as Executive Chairman of the Board of Directors
3/4/2019
Opsens Inc. is pleased to announce the appointment of Mr. Alan Milinazzo as Executive Chairman of the Board of Directors.